Rein Therapeutics Inc (RNTX)

$1.02 0.00 (N/A)
Market Cap 87.25M
Revenue (ttm) 0.00
Net Income (ttm) -49.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 441,500
Avg Vol 726,656
Day's Range N/A - N/A
Shares Out 85.54M
Stochastic %K 21%
Beta 1.35
Analysts Sell
Price Target $8.00

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 802 1989
Address:
12407 N. Mopac Expy., Suite 250 #390, Austin, United States
DARKP00L
DARKP00L Jun. 1 at 11:07 AM
$RNTX 06:42 on Jun. 01 2026 HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8 #tradeideas
0 · Reply
MicsMugz
MicsMugz May. 29 at 6:00 PM
$RNTX $1.14 Resistance
0 · Reply
Muathmj
Muathmj May. 28 at 4:17 PM
$RNTX to the moon
0 · Reply
3stacks
3stacks May. 21 at 3:08 AM
$RNTX picked up some under $1
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 20 at 11:44 PM
$AIRS $OBIO $RNTX $TOI
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 20 at 10:28 PM
$AIRS $KZIA $RNTX airs crushing it - rntx hasnt even started yet - kzia - flying sweet and pretty
0 · Reply
SevenPhigs27
SevenPhigs27 May. 20 at 9:55 PM
$RNTX Took a starter. GLTA
0 · Reply
10baggerPete
10baggerPete May. 19 at 5:22 PM
$RNTX below a buck ... Oops!
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 18 at 1:58 PM
$KZIA $AIRS $OBIO $RNTX Were here all week
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 13 at 12:54 AM
$RNTX $AIRS $OPEN $RMCO
0 · Reply
Latest News on RNTX
Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

2026-06-01T10:00:14.000Z - 3 days ago

Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

Rein Therapeutics Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 7 days ago

Rein Therapeutics Proxy statement: Proxy filing

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026, 8:00 AM EDT - 17 days ago

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

Rein Therapeutics Quarterly report: Q1 2026

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Apr 30, 2026, 8:00 PM EDT - 5 weeks ago

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics provides update on RENEW clinical trial

2026-04-29T14:52:11.000Z - 5 weeks ago

Rein Therapeutics provides update on RENEW clinical trial

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics files to sell 30M shares of common stock

2026-04-28T21:45:51.000Z - 5 weeks ago

Rein Therapeutics files to sell 30M shares of common stock

Rein Therapeutics Registration statement: Registration filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Rein Therapeutics Registration statement: Registration filing

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

2026-04-02T15:00:37.000Z - 2 months ago

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

Rein Therapeutics Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 2 months ago

Rein Therapeutics Annual report: Q4 2025

Rein Therapeutics downgraded to Hold from Buy at Brookline

2026-01-21T14:20:17.000Z - 4 months ago

Rein Therapeutics downgraded to Hold from Buy at Brookline

Rein Therapeutics Slides: Corporate presentation

Jan 21, 2026, 7:00 AM EST - 4 months ago

Rein Therapeutics Slides: Corporate presentation

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

2026-01-20T13:12:26.000Z - 4 months ago

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

Rein Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

Rein Therapeutics Quarterly report: Q3 2025

Rein Therapeutics announces publication on LTI-03

2025-11-06T13:27:27.000Z - 7 months ago

Rein Therapeutics announces publication on LTI-03

Rein Therapeutics upgraded to Buy from Hold at Brookline

2025-11-03T17:55:07.000Z - 7 months ago

Rein Therapeutics upgraded to Buy from Hold at Brookline

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

2025-11-03T12:36:11.000Z - 7 months ago

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

2025-10-09T11:36:09.000Z - 8 months ago

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Oct 9, 2025, 7:30 AM EDT - 8 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics initiated with a Buy at H.C. Wainwright

2025-09-22T10:10:15.000Z - 9 months ago

Rein Therapeutics initiated with a Buy at H.C. Wainwright

Rein Therapeutics announces publication of data on LTI-03 in IPF

2025-09-17T11:35:19.000Z - 9 months ago

Rein Therapeutics announces publication of data on LTI-03 in IPF

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Sep 17, 2025, 7:30 AM EDT - 9 months ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics files to sell 10M shares of common stock for holders

2025-09-03T21:05:11.000Z - 9 months ago

Rein Therapeutics files to sell 10M shares of common stock for holders

Rein Therapeutics Registration statement: Registration Filing

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Rein Therapeutics Registration statement: Registration Filing

Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

2025-08-19T12:05:29.000Z - 10 months ago

Rein announces U.K. MHRA authorized to initiate Phase 2 ‘RENEW’ trial

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 19, 2025, 8:00 AM EDT - 10 months ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics downgraded to Hold from Buy at Brookline

2025-08-19T09:05:31.000Z - 10 months ago

Rein Therapeutics downgraded to Hold from Buy at Brookline

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Aug 14, 2025, 5:00 PM EDT - 10 months ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Quarterly report: Q2 2025

Rein Therapeutics enters agreements for up to $21M in financing

2025-07-30T12:36:02.000Z - 11 months ago

Rein Therapeutics enters agreements for up to $21M in financing

Rein Therapeutics Transcript: AGM 2025

Jul 23, 2025, 9:00 AM EDT - 11 months ago

Rein Therapeutics Transcript: AGM 2025

Rein Therapeutics Proxy statement: Proxy Filing

Jul 11, 2025, 8:00 AM EDT - 11 months ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 24, 2025, 10:11 AM EDT - 1 year ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Rein Therapeutics Proxy statement: Proxy Filing

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Jun 12, 2025, 5:18 PM EDT - 1 year ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics says first patient dosed in Renew Phase 2 trial of LTI-03

2025-05-27T11:05:11.000Z - 1 year ago

Rein Therapeutics says first patient dosed in Renew Phase 2 trial of LTI-03

IQV

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025, 4:51 PM EDT - 1 year ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Registration statement: Registration Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Registration statement: Registration Filing

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:09 PM EDT - 1 year ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Slides: Corporate presentation

May 15, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Slides: Corporate presentation

Rein Therapeutics Earnings release: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Rein Therapeutics Earnings release: Q1 2025

Rein Therapeutics Quarterly report: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Rein Therapeutics Quarterly report: Q1 2025

Rein Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 12:00 PM EDT - 1 year ago

Rein Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 4:17 PM EDT - 1 year ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

DARKP00L
DARKP00L Jun. 1 at 11:07 AM
$RNTX 06:42 on Jun. 01 2026 HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8 #tradeideas
0 · Reply
MicsMugz
MicsMugz May. 29 at 6:00 PM
$RNTX $1.14 Resistance
0 · Reply
Muathmj
Muathmj May. 28 at 4:17 PM
$RNTX to the moon
0 · Reply
3stacks
3stacks May. 21 at 3:08 AM
$RNTX picked up some under $1
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 20 at 11:44 PM
$AIRS $OBIO $RNTX $TOI
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 20 at 10:28 PM
$AIRS $KZIA $RNTX airs crushing it - rntx hasnt even started yet - kzia - flying sweet and pretty
0 · Reply
SevenPhigs27
SevenPhigs27 May. 20 at 9:55 PM
$RNTX Took a starter. GLTA
0 · Reply
10baggerPete
10baggerPete May. 19 at 5:22 PM
$RNTX below a buck ... Oops!
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 18 at 1:58 PM
$KZIA $AIRS $OBIO $RNTX Were here all week
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 13 at 12:54 AM
$RNTX $AIRS $OPEN $RMCO
0 · Reply
TW_Research
TW_Research May. 10 at 1:41 PM
Portfolio now up 100% on the year and the future looking bright. Subscribe to the free newsletter to see what stocks we are following. $ALMU $KZIA $WATT $RNTX are the recent winners. But there are more.https://twresearchgroup.com/2026/05/the-bull-market-continues-into-micro-cap-earnings-week/
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 8 at 7:40 PM
$AIRS $RNTX $RMCO $OPEN - gonna print money all summer
1 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 8 at 1:34 AM
$TOI great earnings mgt - keep walking her up $AIRS - your up next $RNTX - loving the action - no brainer buy $OBIO - steady eddie - buy dips
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 7 at 11:23 AM
$RMCO $AIRS $CYPH $RNTX Is coming for them all!
0 · Reply
longterminvs
longterminvs May. 7 at 3:38 AM
$RNTX https://x.com/Rein_Tx/status/2052052039937531974?s=20
0 · Reply
TW_Research
TW_Research May. 7 at 2:18 AM
$RNTX Amazing how little interest there is here. That will change soon enough.
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 6 at 2:54 PM
$AIRS $KZIA $OBIO $RNTX Rntx - deal closed monday - starting to wake up - major catalyst less than 6'm Smart money & clean (derisked and no overhang w a clean cap table at 1$ - ill join em - no brainer Airs - wont be denied - space is heating up - shorts got this wrong Obio - great news today - i buy Kzia - up 100 percent and still holding
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 5 at 10:19 PM
$AIRS $CYPH $OPEN $RNTX
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 5 at 2:56 PM
$CYPH $RNTX $OPEN $AIRS Cyph - boom shakala New adds - airs and rntx Let the fun begin
0 · Reply
10baggerPete
10baggerPete May. 4 at 10:32 PM
$RNTX 3 day rule, ya cheeky pups!
0 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 4 at 1:45 PM
$AIRS $RNTX $OBIO $KZIA All looking good and just gonna get better
1 · Reply
ItsAllAboutBeingFirst
ItsAllAboutBeingFirst May. 1 at 9:40 PM
So good for $KZIA and the space .. just entered $AIRS $RNTX.... let the fun begin
0 · Reply